A5046719320- Acute Myeloid Leukemia Research
- Histone Deacetylase Inhibitors Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Protein Degradation and Inhibitors
- Retinoids in leukemia and cellular processes
- Multiple Myeloma Research and Treatments
- DNA Repair Mechanisms
- Immune cells in cancer
- Neutropenia and Cancer Infections
- HIV/AIDS drug development and treatment
- Cancer therapeutics and mechanisms
- Lymphoma Diagnosis and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Epigenetics and DNA Methylation
- Renal Transplantation Outcomes and Treatments
- Hematological disorders and diagnostics
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
Johns Hopkins University
2016-2025
Johns Hopkins Medicine
2014-2025
Sidney Kimmel Comprehensive Cancer Center
2015-2024
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
2005-2023
University of Maryland, Baltimore
2008-2023
University of Baltimore
2000-2023
Johns Hopkins Hospital
2014-2022
University of Siena
2021
University of Maryland Medical Center
2007-2018
U-M Rogel Cancer Center
2001-2014
The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or yielded new information regarding factors prognostic importance, are intended aid physicians decision-making. These Insights focus recent select updates Guidelines, including familial genetic alterations AML, postinduction postremission strategies low-risk acute promyelocytic leukemia...
Purpose Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated effect of age on NMA haplo-BMT outcomes patients 50 to 75 years. Patients and Methods A retrospective analysis was performed 271 consecutive with hematologic malignancies, years, who received NMA, T-cell–replete high-dose post-transplantation cyclophosphamide. Results The median 61 115 (42%) 59, 129 (48%) 60 69, 27 (10%)...
Composite endpoints that not only encompass mortality and relapse, but other critical post-transplant events such as graft-versus-host disease, are being increasingly utilized to quantify survival without significant morbidity after allogeneic blood or marrow transplantation. High-dose, post-transplantation cyclophosphamide reduces severe disease with transplantation, making composite this management particularly interesting. We retrospectively analyzed 684 adults hematologic malignancies...
Our understanding of phenotypic and functional signatures CD8+ T cell dysfunction in acute myeloid leukemia (AML) is limited. Deciphering these deranged states how they are impacted by induction chemotherapy essential for incorporation novel immune-based strategies to restore maintain antileukemia immunity.We utilized high-dimensional immunophenotyping, gene expression, studies characterize peripheral blood bone marrow cells 72 AML patients at diagnosis after chemotherapy.Our data suggest...
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of blasts in peripheral blood, bone marrow, and/or other tissues. It most common form acute among adults and accounts for largest number annual deaths from leukemias United States. Like AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy. rare aggressive proliferation precursors cells that frequently involves skin, central nervous system, organs This discussion...
Abstract Purpose: Vascular endothelial growth factor (VEGF) promotes acute myelogenous leukemia (AML) cell and survival may contribute to drug resistance. bevacizumab, an anti-VEGF monoclonal antibody, exhibits clinical activity against diverse malignancies when administered with cytotoxic chemotherapy. We conducted a Phase II trial of bevacizumab after chemotherapy adults refractory or relapsed AML, using timed sequential therapy (TST) approach. Experimental Design: 10 mg/kg was on day 8...
Myeloid sarcoma (MS) is a neoplasm of immature granulocytes, monocytes, or both involving any extramedullary site. The correct diagnosis MS important for adequate therapy, which often delayed because high misdiagnosis rate. To evaluate the lineage differentiation neoplastic cells in by immunohistochemistry, and to correlate results with clinicopathologic findings cytogenetic studies. Histologic immunohistochemical examinations were performed on formalin-fixed paraffin-embedded tissue samples...
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV ET characterized by significant thrombohemorrhagic complications high risk transformation to MF acute myeloid leukemia. The diagnosis management has evolved since identification mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss recommendations outlined Guidelines for...
Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy reduce the incidence of neutropenia. This selection from NCCN Guidelines for MGFs focuses on evaluation regimen- and patient-specific risk development febrile neutropenia (FN), prophylactic use prevention chemotherapy-induced FN, assessing risks benefits MGF in clinical practice.
Summary Patients with acute myeloid leukaemia ( AML ) or myelodysplastic syndrome MDS may respond to treatment epigenetic‐modifying agents. Histone deacetylase inhibitors synergize hypomethylating This phase 1 dose‐escalation study was designed determine the maximum tolerated dose, recommended 2 safety and tolerability of vorinostat plus decitabine in patients relapsed/refractory , newly‐diagnosed intermediate‐ high‐grade . Thirty‐four received concurrent therapy 37 sequential followed by...
Abstract Somatic TP53 mutations and 17p deletions with genomic loss of occur in 37% to 46% acute myeloid leukemia (AML) adverse-risk cytogenetics correlate primary induction failure, high risk relapse, dismal prognosis. Herein, we aimed characterize the immune landscape TP53-mutated AML determine whether abnormalities identify a patient subgroup that may benefit from immunotherapy flotetuzumab, an investigational CD123 × CD3 bispecific dual-affinity retargeting antibody (DART) molecule. The...
Management of febrile neutropenia (FN) is an integral part supportive care for patients undergoing cancer treatment. The NCCN Guidelines Hematopoietic Growth Factors provide suggestions appropriate evaluation, risk determination, prophylaxis, and management FN. These are intended to guide clinicians in the use growth factors select treatment nonmyeloid malignancies. Insights highlight important updates regarding incorporation newly FDA-approved granulocyte-colony stimulating factor...
Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation abnormal mast cells and their accumulation in skin and/or various extracutaneous organs. Systemic mastocytosis most common form diagnosed adults, characterized by cell infiltration one or more organs (with without involvement). The identification KIT D816V mutation emergence novel targeted therapies have significantly improved diagnosis treatment systemic mastocytosis. However, certain aspects clinical...
for core-binding factor (CBF) AML (t(8;21); inv(16); (t(16;16)) was performed at each institution prior to enrollment, and patients were excluded if CBF positive.The study conducted in accordance with the Declaration of Helsinki after approval by ethics committee participating center.
Purpose: After failure of hypomethylating agents (HMA), patients with myelodysplastic syndromes (MDS) have dismal survival and no approved treatment options.Patients Methods: We conducted a phase 1b investigator-initiated trial ipilimumab in higher risk MDS who failed HMAs. Patients received monotherapy at two dose levels (DL; 3 10 mg/kg) an induction followed by maintenance phase. Toxicities responses were evaluated CTCAE.4 IWG-2006 criteria, respectively. also performed immunologic assays...